Related references
Note: Only part of the references are listed.CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA
Takao Hirano et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
Robert L. Avery et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2017)
Netrin-1 in cancer: Potential biomarker and therapeutic target?
Umut Kefeli et al.
TUMOR BIOLOGY (2017)
Truncated netrin-1 contributes to pathological vascular permeability in diabetic retinopathy
Khalil Miloudi et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Netrin 1 regulates blood-brain barrier function and neuroinflammation
Cornelia Podjaski et al.
BRAIN (2015)
CD146 acts as a novel receptor for netrin-1 in promoting angiogenesis and vascular development
Tao Tu et al.
CELL RESEARCH (2015)
Study of 27 Aqueous Humor Cytokines in Type 2 Diabetic Patients with or without Macular Edema
Ning Dong et al.
PLOS ONE (2015)
Vitreous and Plasma VEGF Levels as Predictive Factors in the Progression of Proliferative Diabetic Retinopathy after Vitrectomy
Jiaxing Wang et al.
PLOS ONE (2014)
Endothelial Expression of Guidance Cues in Vessel Wall Homeostasis Dysregulation Under Proatherosclerotic Conditions
Janine M. van Gils et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Bevacizumab for the management of diabetic macular edema
Francisco Rosa Stefanini et al.
WORLD JOURNAL OF DIABETES (2013)
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Daniel F. Martin et al.
OPHTHALMOLOGY (2012)
A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard
Christine Schmucker et al.
PLOS ONE (2012)
The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review
John A. Ford et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package
Thunyarat Anothaisintawee et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2012)
Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab
K. Matsuyama et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2010)
Netrin-1 role in angiogenesis To be or not to be a pro-angiogenic factor?
Marie Castets et al.
CELL CYCLE (2010)
Netrin-1 Regulates Th1/Th2/Th17 Cytokine Production and Inflammation through UNC5B Receptor and Protects Kidney against Ischemia-Reperfusion Injury
Raghu Kempegowda Tadagavadi et al.
JOURNAL OF IMMUNOLOGY (2010)
Platelets take up the monoclonal antibody bevacizumab
Henk M. W. Verheu et al.
CLINICAL CANCER RESEARCH (2007)
Current treatment approaches in diabetic macular edema
Carsten H. Meyer
OPHTHALMOLOGICA (2007)
Vascular endothelial growth factor: Basic science and clinical progress
N Ferrara
ENDOCRINE REVIEWS (2004)
The axonal attractant Netrin-1 is an angiogenic factor
KW Park et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales
CP Wilkinson et al.
OPHTHALMOLOGY (2003)
Share Paper
